Post-earnings recap
Reported
Tue, Mar 21, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report reflects Viking Therapeutics' ongoing challenges, particularly with revenue visibility. The stock dropped 3.88% following the announcement, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear financial direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | +16.28% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach, emphasizing the importance of their clinical pipeline. They did not provide any updates on future earnings guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and development programs.